GLP-1 Side Effects: What's Normal and What's Not

^{Disclosure: Calorie Critic is reader-supported. When you buy through links on our site, we may earn a commission. Our editorial opinions and Calorie Critic Scores are our own and are never influenced by affiliate partnerships.}

Nearly half of the people in Novo Nordisk's own trials threw up at some point. That is the headline number no press release wants to run with. In the STEP 1–3 pooled safety analysis published in Diabetes, Obesity and Metabolism, 43.9% of participants on semaglutide 2.4mg reported nausea, 29.7% reported diarrhea, 24.5% reported vomiting, and 24.2% reported constipation. The number the headlines tend to skip: 98.1% of those events were mild to moderate, the typical nausea episode lasted 8 days, and only 4.5% of STEP 1 participants discontinued because of GI side effects.

The side effects are real. They are also mostly temporary, mostly manageable, and mostly not a reason to stop. What matters is knowing the difference between normal discomfort and something that warrants a phone call.

That distinction got a fresh spotlight last month. On March 5, 2026, the FDA sent Novo Nordisk a warning letter citing "serious violations" in how the company tracked and reported side effects, including three deaths (one by suicide) that were not reported within the required 15-day window. One of the flagged cases was a patient report of suicidal ideation that came in during December 2024 and sat unreviewed until FDA inspectors flagged it in February 2025. The lapse was not about concealing a new side effect. It was about how quickly information moves from patient to provider to company to regulator. Which is the exact dynamic every GLP-1 patient should care about, whether they are on branded Wegovy or compounded semaglutide from a telehealth brand.

This guide breaks down what is normal, what is not, when to call your provider, when to go to the ER, and why the single most important variable in your GLP-1 safety is not the drug itself.

GLP-1 stands for glucagon-like peptide-1, a hormone your gut already releases after you eat. Drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) mimic that hormone at higher doses and for longer. They slow gastric emptying, signal fullness to your brain, and blunt the appetite signals that drive most overeating. That mechanism is why the drugs work. It is also why they cause the side effects they cause.

Think of your stomach on a GLP-1 as the checkout line at a grocery store where the cashier is deliberately slow. Food still comes in. It just sits in your stomach longer than your body is used to. Pile a big, fatty meal on top of what is already backed up, and your body pushes back, sometimes literally.

Every major GI side effect on the list comes from that slower emptying. The nausea, the fullness, the reflux, the burps. They are not a glitch. They are the drug doing its job.

The side effects track the dose. They peak during the 20-week escalation period, when your provider steps you up from 0.25mg to the maintenance dose. They fade once your body adjusts. According to the STEP 3 trial, nausea peaked at approximately 25% of participants at week 20 and then declined to around 15% for the rest of the trial.

These are the ones almost everyone will feel at some point, especially in the first 8 to 12 weeks.

Nausea. The most common, by a wide margin. 43.9% in the STEP 1–3 pooled analysis, compared to 16.1% on placebo. Individual episodes last a median of 8 days. Typical pattern: nausea starts 24 to 72 hours after a dose increase, lasts 3 to 7 days at that level, and fades before the next step up. By 4 to 8 weeks on your maintenance dose, most patients report it is gone or nearly gone.

What's normal: mild queasiness, loss of interest in large meals, a sense that food is no longer the most exciting part of your day. What's not: vomiting that persists past 48 hours, inability to keep fluids down, dizziness when standing, dark urine.

Vomiting. 24.5% in the trials vs 6.3% on placebo. Median episode: 2 days. Usually happens after meals that are too big, too fast, or too fatty. The lesson most patients learn by week 4 is that portion sizes and food choices matter more on a GLP-1 than they did before.

Diarrhea. 29.7% vs 15.9%. Median duration: 3 days.

Constipation. 24.2% vs 11.1%. This one is the quiet problem. Median duration was 27 days in STEP 3, significantly longer than the other GI effects. Hydration and fiber help. Fiber supplements and stool softeners are reasonable to discuss with your provider if it drags on.

Sulfur burps. Not a line item in the STEP trials but a top complaint in every GLP-1 subreddit. Slower gastric emptying means food ferments longer, and certain foods (eggs, red meat, cruciferous vegetables) produce hydrogen sulfide gas that comes back up smelling like rotten eggs. Unpleasant, not dangerous, and usually fixed by smaller portions and avoiding the trigger foods.

Fatigue. Reported by 11% of Wegovy users in clinical trials per GoodRx's summary of the FDA label, and less than 5% of Ozempic users. Usually tied to reduced caloric intake, blood sugar dips, or mild dehydration from GI symptoms. If you are eating 900 calories a day because nothing sounds appealing, you are going to feel tired. The fix is rarely stopping the medication. It is eating more protein and drinking more water.

Hair loss. Roughly 3% of Wegovy users in clinical trials reported alopecia, versus about 1% on placebo. Tirzepatide trials saw up to 6%. This is not semaglutide attacking your hair follicles. It is telogen effluvium, a stress response to rapid weight loss that happens with any major calorie restriction, including bariatric surgery and crash dieting, per dermatologists who have studied the phenomenon. The hair almost always grows back. Adequate protein (0.7 to 1g per pound of goal body weight) reduces the risk.

Injection site reactions. Mild redness or swelling at the injection site. Rotating injection sites (abdomen, thigh, upper arm) solves it for most people.

These are rare. They are also real, and the correct response to any of them is a same-day call to your provider or a trip to the ER, not a Google search to see if it fades on its own.

Acute pancreatitis. Severe, persistent abdominal pain that radiates to your back, often with nausea and vomiting that feels different from your usual pattern. The Ozempic FDA label explicitly tells patients to discontinue the medication and seek immediate evaluation if pancreatitis is suspected, and not to restart if it is confirmed.

Acute gallbladder disease. Rapid weight loss from any cause raises gallstone risk, and semaglutide adds to it. Symptoms: severe pain in the upper right abdomen, sometimes radiating to the right shoulder, often with nausea, vomiting, and fever. The Wegovy label lists it as a known risk requiring clinical follow-up.

Thyroid C-cell tumors (black box warning). Semaglutide carries an FDA black box warning for risk of medullary thyroid carcinoma (MTC) based on rodent studies. The human picture is less clear. A 2023 systematic review and meta-analysis concluded that semaglutide use was not associated with increased cancer risk, with a high grade of evidence. A French observational study did flag a signal for 1-3 year use, but real-world limitations mean the clinical trial evidence carries more weight. Regardless, anyone with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2) should not take semaglutide. A new lump or swelling in your neck, hoarseness, or trouble swallowing warrants a call.

Acute kidney injury. Usually secondary to severe dehydration from prolonged vomiting and diarrhea. If you cannot keep fluids down for 24 hours, this becomes a real risk, not a theoretical one.

Hypoglycemia. Primarily a concern if you are also taking insulin or a sulfonylurea. GLP-1 monotherapy in non-diabetic weight loss patients rarely causes low blood sugar.

Mental health changes. The FDA investigated a possible link between GLP-1s and suicidal ideation in 2024 and did not find evidence that the drugs cause suicidal thoughts, though the agency acknowledged it could not definitively rule out a small risk. The March 2026 FDA warning letter to Novo Nordisk specifically cited an unreported case of suicide among semaglutide patients. If you experience new or worsening depression, anxiety, or suicidal thoughts on a GLP-1, call your provider immediately. Do not wait to see if it resolves.

Most GLP-1 side effects are predictable. They show up in a pattern that tracks the five-month dose escalation, peak around week 20, and fade after.

If your provider escalates you faster than every four weeks, or does not pause the schedule when you are struggling, that is a signal to push back or find a new provider.

Most side effects can be managed at home with hydration, smaller meals, and time. Some cannot.

Call your provider within 24 hours if:

Go to the ER or call 911 for:

Here is what the clinical data and the March 2026 FDA action both point to, and what most GLP-1 side effect articles miss. The dangerous thing about these medications is not any single adverse event. It is a provider who is not paying attention.

A good GLP-1 provider starts you at 0.25mg. Escalates every four weeks, not faster. Checks in at each step. Asks about nausea, vomiting, constipation, energy, and mood. Responds when something is wrong instead of auto-dispensing your next pen. Slows your escalation when you are struggling. Has someone reachable when a patient reports suicidal thoughts in December so the review does not wait until February.

The FDA's warning letter to Novo Nordisk was about reporting lag at the manufacturer level. The same principle applies at the provider level. If your GLP-1 company ships your medication every four weeks with no appointment, no check-in, and no real human you can reach when something goes wrong, you are not being monitored. You are being dispensed. Those are different services. Most telehealth GLP-1 providers charge similar prices for both, so you should know which one you are paying for.

We track provider quality on exactly this dimension in our reviews. If your current provider falls short, it is worth looking at the best GLP-1 providers and comparing what real clinical oversight looks like.

How long do GLP-1 side effects last? Most GI side effects last a few days to a few weeks per dose increase, with the full pattern fading by month 4 to 6 on a stable maintenance dose. In the STEP 1–3 pooled analysis, the median nausea episode lasted 8 days, vomiting 2 days, and diarrhea 3 days.

Are GLP-1 side effects dangerous? The common ones (nausea, vomiting, diarrhea, constipation) are uncomfortable but rarely dangerous when managed with hydration and smaller meals. 98.1% of GI events in the trials were classified as mild to moderate. Serious side effects (pancreatitis, gallbladder disease, thyroid concerns, kidney injury) are rare but real and require immediate medical attention.

What is the worst side effect of Ozempic? Pancreatitis is the most serious common side effect because it can escalate quickly and requires discontinuing the medication permanently if confirmed. Severe, persistent abdominal pain radiating to the back is the classic presentation.

Does everyone get nausea on semaglutide? No. In the STEP trials, 43.9% of patients on the 2.4mg dose reported nausea. That means 56.1% did not, or had symptoms mild enough not to report. Slower escalation and smaller, lower-fat meals reduce nausea risk significantly.

Can you stop GLP-1 side effects without stopping the medication? For most people, yes. Eating smaller meals, reducing fatty and fried foods, staying hydrated, taking it slow on protein-heavy meals, and letting your provider know when it is time to pause the escalation all help. Anti-nausea medications like ondansetron are sometimes prescribed for short-term relief.

When should I stop taking my GLP-1? Talk to your provider first, not a Reddit thread. You should contact them immediately if you experience signs of pancreatitis, gallbladder disease, severe dehydration, allergic reaction, or suicidal thoughts. For common GI side effects, the usual move is to pause at your current dose rather than stop entirely.

Does hair loss from Ozempic grow back? Almost always, yes. GLP-1 hair loss is telogen effluvium triggered by rapid weight loss, not a direct effect of the drug on hair follicles. It typically resolves within 6 to 12 months of weight stabilization, especially with adequate protein intake.

Before starting any GLP-1, and before making changes to your regimen, talk to a real clinician. Not a telehealth intake form. A good provider will review your medical history, discuss your goals, build a dosing plan that matches your situation, and stay reachable when side effects show up. If the provider you are considering does not do all four, keep looking.

For more on how to evaluate a GLP-1 provider, see our guide to choosing a GLP-1 provider and our Hims vs. Ro comparison. For daily food strategies to minimize side effects, see our guide to macro tracking on GLP-1s.

Calorie Critic is a publication of Hoot Fitness, LLC.